Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology portfolio by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the first step toward negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3), a key immune checkpoint.
This potential collaboration is strategically important because it merges two complementary approaches in cancer therapy. Ifowonco’s program focuses on developing orally available small-molecule LAG-3 inhibitors, which stand in contrast to the currently approved LAG-3 therapies that are monoclonal antibodies administered intravenously. Onco-Innovations brings its expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications.
The rationale behind this combination is rooted in the emerging understanding that DDR inhibitors can increase the immunogenicity of tumours, making them more susceptible to immune attack. By adding a LAG-3 inhibitor, which releases the brakes on T-cell activation, the dual approach may offer a more potent and sustained anti-tumour effect. This is particularly relevant for solid tumours that have historically been resistant to immunotherapy.
If the definitive agreement is completed, the companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations’ ONC010 program. This phased approach allows for rigorous scientific validation before combining the two modalities.
CEO Thomas O’Shaughnessy highlighted the potential impact of this agreement, stating that it could position the company “at the intersection of precision oncology and next-generation cancer immunotherapy.” This underscores the strategic importance of the move, as it aligns Onco-Innovations with cutting-edge trends in cancer treatment that emphasize combination therapies and oral bioavailability for improved patient convenience and adherence.
The LOI is non-binding, meaning that the terms could change or the deal could fall through, but the announcement signals a proactive effort by Onco-Innovations to diversify its pipeline and address significant unmet needs in oncology. For patients, the development of oral LAG-3 inhibitors could offer a more convenient alternative to intravenous infusions, potentially improving quality of life during treatment. For the company, it represents a potential growth avenue that could strengthen its position in the competitive immuno-oncology market.
For more information on the full press release, visit https://ibn.fm/E63Ne. For the latest news on Onco-Innovations, see https://ibn.fm/ONNVF.
